I like the stock at deep on sale price 80 yesterday
hope the stock heading back retesting the 250 level
lnkd heading below 200 soon ... hehehe
=== LinkedIn had been looking solid this summer, establishing a well defined uptrend after a previous earnings-induced gap down. But today's big drop puts the kibosh on that more attractive price trajectory.
LinkedIn could be headed below $200 in the near-term.
biogen stock hit the 322 level in 3 occasions after ER
today is the 3rd and if you don't cash out your chip it's dummy
I'm waiting for my 4th trip from this baby next week = green $$$
more down side to go
ready to break the 200 level soon
still have 2 hours to go to achieve that goal toward eod
not a stock to touch on a bad ER day = market unloading
+10 point gain from yesterday's low 80 (now 90)
gotta love the biotech rally from bottom = green $$$
i like alibaba's visions (see below) ...
=== Alibaba (BABA) said it will invest $1 billion in its cloud computing division Aliyun. The move is being viewed as an attempt to intensify competition with Amazon’s Web Services unit. These funds will be utilized to create Aliyun data centers in Europe, Japan, Singapore and Middle East. Aliyun’s president Simon Hu said: “Our goal is to overtake Amazon in four years, whether that's in customers, technology, or worldwide scale.”
Additionally, Alibaba is looking to strengthen its network of global cloud computing alliances. This will create a cloud-based environment which can assist businesses from the very first day of operations. Aliyun is entering into a strategic partnership with China’s largest software vendor Yonyou Software Co. Ltd or Yonyou which will help them collaborate on various fronts.
baba is heading to retest the 52-week low 76 shortly
i'm watching for an entry point = patience is a good virtue
just caught this news = thank you for informing it
=== Medivation declares a two-for-one stock split of its common stock to be effected through a stock dividend; confirms Astellas' (ALPMY) Q1 results (MDVN) : The co confirmed that today its alliance partner Astellas Pharma (ALPMY) reported its financial results for the quarter ended June 30, 2015. Astellas reported, among other things, that U.S. net sales of XTANDI capsules were $298.4 million for the quarter ended June 30, 2015, an increase of 33% above the reported net sales of $224.0 million in the quarter ended March 31, 2015. Based on information provided by Astellas, approximately half of the $74.4 million increase in net sales was the result of higher volume, which included an increase in underlying demand (low to mid-teens percent growth, as a percentage of the March quarter sales), and the remaining increase was related to price elements, including changes in the gross-to-net discount. Based on information provided by Astellas, XTANDI U.S. net sales of $298.4 million for the quarter ended June 30, 2015, included a favorable adjustment related to changes in prior period estimates of deductions against gross sales, as recorded by Astellas, of approximately $2.8 million.
nice biotech sector rally today thanks to amgen = woo hoo
i dont own amgn but many other young biotech stars